Abstract Number: 1471 • ACR Convergence 2022
Trends and Predictors of Hospitalizations Due to Acute Myocardial Infarction in Systemic Lupus Erythematosus Patients
Background/Purpose: Cardiovascular events occur more frequently and with earlier onset in patients with Systemic Lupus Erythematosus (SLE) compared with healthy individuals. Several studies have concluded…Abstract Number: 1592 • ACR Convergence 2022
Serious Infections in SLE- Incidence, Associated Factors, Impact and Trends over Two Decades
Background/Purpose: Infections are a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). We assessed the incidence and risk factors for major infections…Abstract Number: 1697 • ACR Convergence 2022
Measurements of Specific Activation Through the Lectin -or Classical Pathway of Complement in Patients with SLE
Background/Purpose: In systemic lupus erythematosus (SLE), the complement system is activated and commonly thought to occur through the classical pathway (CP) [1]. However, our previous…Abstract Number: 1753 • ACR Convergence 2022
Temporal Trends of SLE Mortality Among Various Ethnic Categories Across the United States: 2001-to 2020 Analysis from WONDER Database
Background/Purpose: Racial disparities in SLE have been well described. Blacks are disproportionately affected, and have a higher incidence, disease severity, and mortality compared to Whites,…Abstract Number: 2058 • ACR Convergence 2022
Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus
Background/Purpose: Cognitive impairment (CI) is prevalent in SLE and negatively impacts social and occupational engagement. There is a need for a patient-reported outcome measure (PROM)…Abstract Number: 2076 • ACR Convergence 2022
Unfavorable Outcomes Associated with Current Standard of Care in the Management of Patients with Systemic Lupus Erythematosus
Background/Purpose: The effectiveness of current standard of care treatment including corticosteroids (CS) in Systemic Lupus Erythematosus (SLE) is limited and has potential side-effects. Given the…Abstract Number: 2096 • ACR Convergence 2022
Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus
Background/Purpose: The prompt identification of patients with systemic lupus erythematosus (SLE) at risk of or in flare strongly influences the prognosis of the disease. Cell-bound…Abstract Number: 2202 • ACR Convergence 2022
Association of Visit-based Retention and Receipt of Serologic Testing with Acute Care Use Among Young Adults with Lupus: A Medicare Cohort Study
Background/Purpose: While high quality lupus care is associated with less damage, the impact of care use patterns and care quality on lupus outcomes remains unclear,…Abstract Number: 0106 • ACR Convergence 2022
A Systematic Review of Racial and Ethnic Disparities in Disease Related Outcomes Among Patients with SLE
Background/Purpose: Racialized patients and ethnic minorities have worse outcomes in SLE. This is likely related to a complex interplay between genetic and non-genetic factors. Numerous…Abstract Number: 0323 • ACR Convergence 2022
Identifying Distinct Phenotypes of Patients with Juvenile Systemic Lupus Erythematosus: Results from a Cluster Analysis by the Egyptian College of Rheumatology (ECR) Study Group
Background/Purpose: Juvenile systemic lupus erythematosus (J-SLE) is a complex autoimmune disease characterized by a great heterogeneity in organs involvement. A better understanding of the organ…Abstract Number: 0340 • ACR Convergence 2022
Birth Order Is a Risk Factor for Systemic Lupus Erythematosus
Background/Purpose: Birth order effects have been described in several immune and non-immune disease states. While some studies have found an increased risk of developing autoimmune…Abstract Number: 0361 • ACR Convergence 2022
Gene Expression Pathways Modulated by Anifrolumab in Systemic Lupus Erythematosus
Background/Purpose: Anifrolumab is a monoclonal antibody to IFN-α receptor 1 that inhibits type I IFN signaling. In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab…Abstract Number: 0586 • ACR Convergence 2022
Transcription Factor Fli-1 Impacts CXCL13 Expression and Renal Inflammation in Lupus-like Nephritis of Adult MRL/lpr Mouse
Background/Purpose: Friend leukemia virus integration 1 (Fli-1) belongs to the Ets family of transcription factors and plays an important role in the development of lupus…Abstract Number: 0645 • ACR Convergence 2022
Lupus Fibroblasts from Non-lesional Skin Exhibit Exaggerated Responses to Inflammatory Cytokines and Upregulate Pro-fibrotic Collagens in Patients with Scarring Lesions
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a manifestation of systemic lupus erythematosus (SLE) that can cause significant patient distress and disfiguration secondary to scar. Scarring…Abstract Number: 0666 • ACR Convergence 2022
HRES-1/Rab4 Controls the Overexpression of CD38 and Depletion of IL-2 in CD4+ T Cells; Potential Involvement in Proinflammatory Lineage Development in SLE
Background/Purpose: HRES-1/Rab4 (Rab4A) is a small GTPase that is overexpressed in SLE patient T cells1,2, mediates the enhanced recycling of CD3 and CD4 cell surface…
- « Previous Page
- 1
- …
- 108
- 109
- 110
- 111
- 112
- …
- 181
- Next Page »
